Our clinical validation study marks a major inflection point for BIOSIRIUS Ltd and its licensing strategy. In partnership with Cambridge University Hospitals, we conducted a prospective cohort study of 206 hospitalised COVID-19 patients to investigate the IL-18 axis in severe viral pneumonia. The results, published in February 2023, demonstrated that free IL-18 levels directly correlate with increased severity and mortality—a finding that underpins the scientific rationale for our patented IP and therapeutic approach. This was the first time free IL-18 was analysed in the context of COVID-19.

​

Read our clinical validation study, published here.